A Phase 1 interventional study of Placebo and Denosumab in Osteoporosis, sponsored by Amgen. Completed. Per ClinicalTrials.gov, last updated 2019-07-24.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 40th largest by enrollment, is the only one that started in 2003, is one of 5 in phase 1, and was the 41st registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 26th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2003, is one of 5 in phase 1, and was the 31st registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the safety and tolerability of denosumab (AMG 162) after a single subcutaneous administration in Japanese postmenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single subcutaneous injection of placebo to denosumab on day 1.
Drug: Placebo
Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
Biological: Denosumab
Administered by subcutaneous injection
Administered by subcutaneous injection
Also known as: AMG 162, Prolia
Number of Participants With Adverse Events
Time frame: From day 1 up to 4 months for participants assigned to the 0.03 or 0.1 mg/kg dose cohorts, up to 6 months for participants assigned to the 0.3 mg/kg dose cohort and for up to 9 months for participants assigned to the 1.0 or 3.0 mg/kg dose cohorts
Area Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab
Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Maximum Observed Concentration of Denosumab (Cmax)
Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Time to Maximum Observed Concentration (Tmax) of Denosumab
Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Apparent Clearance (CL/F) of Denosumab
Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Mean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration
Time frame: Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts
Percent Change From Baseline in Urinary N-Telopeptide Corrected for Urine Creatinine (N-Tx/Cr)
Time frame: Baseline and day 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only).
Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP)
Time frame: Baseline and day 8, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, and 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only)
Percent Change From Baseline in Intact Parathyroid Hormone (iPTH)
Time frame: Baseline and day 2, 3, 5, 8, 15, 29, 57, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only)
This study was conducted at one clinical center in Japan.
| Milestone | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|---|
| Started | 12 | 6 | 6 | 8 | 7 | 6 |
| Received study drug | 10 | 6 | 6 | 6 | 6 | 6 |
| Completed | 10 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 2 | 0 | 0 | 2 | 1 | 0 |
| Participants | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|---|
| Any adverse event | 6 | 2 | 3 | 5 | 6 | 5 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-related adverse events | 4 | 0 | 1 | 3 | 4 | 4 |
| Discontinuation due to adverse events | 0 | 0 | 0 | 0 | 0 | 0 |
| Deaths on study | 0 | 0 | 0 | 0 | 0 | 0 |
| μg*day/mL | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|
| Area Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab | 2.06 ± 0.53 | 15.2 ± 6.7 | 84.3 ± 20.1 | 481 ± 131 | 1790 ± 650 |
| ng/mL | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|
| Maximum Observed Concentration of Denosumab (Cmax) | 99.6 ± 25.8 | 492 ± 166 | 1910 ± 658 | 8690 ± 2170 | 27400 ± 7880 |
| days | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|
| Time to Maximum Observed Concentration (Tmax) of Denosumab | 7.0 (7 to 10) | 12.0 (7 to 21) | 14.0 (7 to 21) | 14.0 (10 to 21) | 14.0 (14 to 42) |
| mL/day/kg | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of Denosumab | 15.3 ± 4.2 | 8.31 ± 4.97 | 3.72 ± 0.89 | 2.20 ± 0.56 | 1.85 ± 0.58 |
| days | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|
| Mean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration | 15.5 ± 4.7 | 22.5 ± 3.9 | 33.6 ± 5.8 | 42.6 ± 7.0 | 51.4 ± 5.8 |
| percent change | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|---|
| Day 2 | 12 ± 11 | 6 ± 4 | -25 ± 8 | -22 ± 11 | -40 ± 7 | -64 ± 4 |
| Day 3 | 19 ± 5 | -6 ± 7 | -30 ± 5 | -40 ± 11 | -51 ± 8 | -60 ± 3 |
| Day 4 | 7 ± 6 | -18 ± 9 | -37 ± 16 | -48 ± 11 | -55 ± 6 | -62 ± 5 |
| Day 5 | 23 ± 10 | -12 ± 12 | -44 ± 5 | -51 ± 8 | -53 ± 8 | -66 ± 6 |
| Day 6 | 9 ± 7 | -1 ± 18 | -53 ± 8 | -62 ± 7 | -59 ± 6 | -72 ± 4 |
| Day 8 | 16 ± 7 | -12 ± 13 | -55 ± 7 | -64 ± 5 | -57 ± 7 | -64 ± 10 |
| Day 11 | 3 ± 8 | -36 ± 5 | -67 ± 5 | -65 ± 7 | -69 ± 6 | -79 ± 3 |
| Day 15 | 4 ± 3 | -51 ± 4 | -68 ± 4 | -71 ± 5 | -71 ± 5 | -77 ± 5 |
| Day 22 | -1 ± 5 | -41 ± 4 | -71 ± 6 | -70 ± 7 | -70 ± 5 | -82 ± 3 |
| Day 29 | -1 ± 5 | -39 ± 5 | -68 ± 3 | -67 ± 6 | -64 ± 7 | -77 ± 4 |
| Day 43 | -1 ± 5 | -33 ± 6 | -67 ± 4 | -68 ± 7 | -69 ± 8 | -81 ± 4 |
| Day 57 | 0 ± 8 | -14 ± 3 | -59 ± 6 | -64 ± 8 | -56 ± 10 | -79 ± 6 |
| Day 71 | -5 ± 7 | -23 ± 6 | -48 ± 10 | -65 ± 6 | -68 ± 5 | -82 ± 3 |
| Day 85 | 8 ± 7 | 4 ± 8 | -48 ± 12 | -58 ± 9 | -68 ± 4 | -83 ± 4 |
| Day 99 | 1 ± 6 | 4 ± 6 | -37 ± 15 | -64 ± 5 | -72 ± 4 | -77 ± 10 |
| Day 113 | -5 ± 6 | 3 ± 4 | -30 ± 15 | -53 ± 10 | -77 ± 3 | -84 ± 2 |
| Day 141 | -7 ± 9 | — | — | -51 ± 5 | -62 ± 5 | -81 ± 3 |
| Day 169 | -15 ± 6 | — | 6 ± 14 | -41 ± 11 | -48 ± 9 | -78 ± 5 |
| Day 197 | -3 ± 5 | — | — | — | -47 ± 8 | -79 ± 4 |
| Day 225 | -7 ± 11 | — | 42.0 | -30 ± 4 | -20 ± 17 | -70 ± 4 |
| Day 253 | -13 ± 10 | — | — | — | -25 ± 14 | -62 ± 5 |
| Day 281 | — | — | — | -13 ± 8 | — | — |
| Day 309 | — | — | — | — | -19 ± 13 | -23 ± 12 |
| percent change | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|---|
| Day 8 | -0.4 ± 2.8 | -6.9 ± 5.9 | 16.6 ± 4.7 | 7.1 ± 2.0 | -0.5 ± 5.1 | 3.1 ± 6.4 |
| Day 15 | -2.1 ± 1.4 | 1.1 ± 3.1 | 8.6 ± 2.0 | 13.2 ± 2.0 | 5.6 ± 5.9 | 11.5 ± 7.8 |
| Day 22 | 1.1 ± 2.8 | 12.7 ± 3.1 | 5.8 ± 2.3 | 7.8 ± 3.8 | 7.0 ± 5.3 | 9.7 ± 5.8 |
| Day 29 | 5.3 ± 2.9 | 8.9 ± 3.6 | 11.0 ± 3.5 | -0.7 ± 2.8 | 5.8 ± 4.2 | -0.4 ± 4.5 |
| Day 43 | 3.6 ± 3.1 | -2.3 ± 2.8 | -7.6 ± 4.3 | -20.3 ± 3.2 | -10.2 ± 4.0 | -14.7 ± 2.6 |
| Day 57 | 2.7 ± 1.6 | -5.9 ± 5.1 | -19.2 ± 2.8 | -33.1 ± 3.1 | -21.0 ± 4.9 | -24.0 ± 2.6 |
| Day 71 | -0.9 ± 3.0 | -5.5 ± 4.8 | -29.0 ± 5.7 | -41.0 ± 2.2 | -36.1 ± 5.2 | -33.9 ± 4.7 |
| Day 85 | 1.3 ± 2.2 | -7.9 ± 6.3 | -27.2 ± 6.1 | -47.7 ± 3.2 | -42.1 ± 4.2 | -43.9 ± 1.9 |
| Day 99 | 1.7 ± 3.2 | -13.1 ± 3.3 | -33.4 ± 5.5 | -49.4 ± 3.0 | -44.0 ± 5.5 | -47.5 ± 2.7 |
| Day 113 | 3.1 ± 2.3 | -0.5 ± 7.1 | -32.6 ± 5.4 | -54.2 ± 2.6 | -49.7 ± 5.1 | -51.4 ± 2.6 |
| Day 141 | -0.2 ± 4.9 | — | — | -57.2 ± 2.6 | -50.7 ± 6.9 | -52.9 ± 3.8 |
| Day 169 | 3.1 ± 4.3 | — | -33.9 ± 7.8 | -52.9 ± 2.5 | -50.1 ± 4.6 | -53.7 ± 2.9 |
| Day 197 | 8.6 ± 5.8 | — | — | — | -43.9 ± 8.6 | -52.5 ± 2.7 |
| Day 225 | 4.6 ± 3.0 | — | 19.5 | -37.1 ± 4.4 | -35.1 ± 8.5 | -48.4 ± 3.6 |
| Day 253 | 11.7 ± 6.5 | — | — | — | -31.9 ± 9.7 | -44.0 ± 4.1 |
| Day 281 | — | — | — | -10.7 ± 6.1 | — | — |
| Day 309 | — | — | — | — | -21.0 ± 14.7 | -26.8 ± 4.8 |
| percent change | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg |
|---|---|---|---|---|---|---|
| Day 2 | 6.9 ± 8.7 | 2.4 ± 13.0 | 10.1 ± 14.1 | 44.0 ± 13.0 | 40.9 ± 19.5 | 129.0 ± 25.2 |
| Day 3 | -8.2 ± 6.1 | 28.9 ± 9.7 | 15.0 ± 18.8 | 71.7 ± 15.8 | 60.7 ± 21.7 | 146.1 ± 46.0 |
| Day 5 | -3.9 ± 6.0 | 47.6 ± 12.2 | 51.8 ± 17.9 | 114.2 ± 27.2 | 103.1 ± 41.8 | 262.1 ± 61.9 |
| Day 8 | -0.7 ± 8.9 | 37.7 ± 20.4 | 76.9 ± 20.7 | 182.4 ± 40.2 | 163.7 ± 38.4 | 353.6 ± 92.4 |
| Day 15 | 11.2 ± 8.9 | 91.5 ± 8.2 | 117.3 ± 33.4 | 146.4 ± 29.0 | 109.4 ± 36.3 | 203.2 ± 27.2 |
| Day 29 | 5.1 ± 7.7 | 97.2 ± 23.8 | 110.9 ± 40.7 | 99.2 ± 16.8 | 70.4 ± 28.3 | 215.2 ± 79.4 |
| Day 57 | 5.3 ± 8.3 | 64.6 ± 18.4 | 120.5 ± 35.5 | 98.0 ± 17.9 | 90.9 ± 20.8 | 177.0 ± 36.8 |
| Day 85 | 17.1 ± 10.2 | 11.9 ± 9.6 | 36.6 ± 24.5 | 76.9 ± 20.2 | 64.4 ± 18.4 | 170.5 ± 40.8 |
| Day 99 | 5.6 ± 7.4 | 19.9 ± 10.5 | 46.4 ± 31.1 | 79.6 ± 13.9 | 44.0 ± 10.9 | 178.5 ± 93.3 |
| Day 113 | -1.2 ± 10.2 | 3.9 ± 15.4 | 29.5 ± 32.8 | 38.5 ± 13.5 | 46.5 ± 10.5 | 155.7 ± 44.5 |
| Day 141 | -3.8 ± 13.9 | — | — | 16.9 ± 11.1 | 22.8 ± 16.6 | 175.4 ± 81.3 |
| Day 169 | -7.9 ± 5.3 | — | -16.7 ± 10.6 | 19.7 ± 8.2 | 21.9 ± 16.1 | 90.2 ± 27.6 |
| Day 197 | -14.9 ± 5.4 | — | — | — | 17.0 ± 9.8 | 100.7 ± 42.1 |
| Day 225 | -5.1 ± 14.1 | — | 15.9 | -30.9 ± 5.0 | 6.2 ± 12.3 | 151.4 ± 83.5 |
| Day 253 | 8.5 ± 12.6 | — | — | — | 10.9 ± 18.1 | 70.8 ± 31.5 |
| Day 281 | — | — | — | -26.1 ± 9.4 | — | — |
| Day 309 | — | — | — | — | 16.6 ± 24.9 | 33.8 ± 11.9 |
Collected over From day 1 up to 4 months for participants assigned to the 0.03 or 0.1 mg/kg dose cohorts, up to 6 months for participants assigned to the 0.3 mg/kg dose cohort and for up to 9 months for participants assigned to the 1.0 or 3.0 mg/kg dose cohorts.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/10 (0%) | 6/10 (60%) |
| Denosumab 0.03 mg/kg | — | 0/6 (0%) | 2/6 (33.3%) |
| Denosumab 0.1 mg/kg | — | 0/6 (0%) | 3/6 (50%) |
| Denosumab 0.3 mg/kg | — | 0/6 (0%) | 5/6 (83.3%) |
| Denosumab 1.0 mg/kg | — | 0/6 (0%) | 6/6 (100%) |
| Denosumab 3.0 mg/kg | — | 0/6 (0%) | 5/6 (83.3%) |
| Denosumab Total | — | 0/30 (0%) | 21/30 (70%) |
| Event | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg | Denosumab Total |
|---|---|---|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 3/10 | 1/6 | 2/6 | 0/6 | 5/6 | 1/6 | 9/30 |
| INJECTION SITE PAINGeneral disorders | 0/10 | 0/6 | 0/6 | 0/6 | 1/6 | 2/6 | 3/30 |
| RHINORRHOEARespiratory, thoracic and mediastinal disorders | 0/10 | 0/6 | 0/6 | 1/6 | 2/6 | 0/6 | 3/30 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/10 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/30 |
| SENSATION OF BLOCK IN EAREar and labyrinth disorders | 0/10 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/30 |
| TINNITUSEar and labyrinth disorders | 1/10 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/30 |
| BLEPHAROSPASMEye disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/30 |
| CONJUNCTIVAL HAEMORRHAGEEye disorders | 0/10 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/30 |
| CONJUNCTIVITISEye disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/30 |
| ABDOMINAL PAINGastrointestinal disorders | 0/10 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 2/30 |
All enrolled participants
| Age, Continuous(years) | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 59.83 ± 2.86 | 59.67 ± 2.34 | 59.50 ± 3.39 | 58.88 ± 3.80 | 56.43 ± 3.95 | 58.67 ± 2.34 | 58.91 ± 3.22 |
| Sex: Female, Male(Participants) | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Female | 12 | 6 | 6 | 8 | 7 | 6 | 45 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Denosumab 0.03 mg/kg | Denosumab 0.1 mg/kg | Denosumab 0.3 mg/kg | Denosumab 1.0 mg/kg | Denosumab 3.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Japanese | 12 | 6 | 6 | 8 | 7 | 6 | 45 |
No study locations are listed for this record.
Plan to share: Undecided
Ran from Sep 2003 to primary completion in Dec 2004, 14 months.
Results were first posted in Jul 2019, 14 years 7 months after primary completion.
Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 14 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab